We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
President Trump says he wants drug pricing legislation passed this year despite the coronavirus pandemic, according to Sen. Chuck Grassley (R-Iowa), the chairman of the Senate Finance Committee. Read More
The FDA added morphine sulfate and epinephrine to the list of compounded drugs under the agency’s temporary policy that allows outsourcing facilities to produce the drugs during the COVID-19 pandemic. Read More
The World Health Organization (WHO) has adopted a resolution calling for the voluntary sharing of patent rights and product data for COVID-19 countermeasures. Read More
HHS is defending the bidding process that led to its $354 million four-year contract with a Virginia-based startup to manufacture active pharmaceutical ingredients (APIs) and finished drugs for emergency situations. Read More
Two senior FDA officials have recused themselves from involvement in agency approval decisions for coronavirus therapeutics or vaccines due to their oversight roles in the administration’s new COVID-19 research initiative. Read More
Gilead Sciences has ramped up the number of remdesivir vials it’s donating to the U.S. government to approximately 940,000 from 607,000, HHS said this week, even as the drugmaker has decided to end two trials it’s conducting on the antiviral. Read More
Rick Bright, former director of HHS’s Biomedical Advanced Research and Development Authority (BARDA), told lawmakers in a hearing yesterday that the frequently cited 12- to 18-month timeline for developing a COVID-19 vaccine is unlikely to pan out. Read More